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A TGFb-Responsive Gene Signature Is Associated
with a Subset of Diffuse Scleroderma with Increased
Disease Severity
Jennifer L. Sargent1, Ausra Milano1, Swati Bhattacharyya2, John Varga2, M. Kari Connolly3,
Howard Y. Chang4 and Michael L. Whitfield1
Systemic sclerosis is a complex disease with widespread skin fibrosis and variable visceral organ involvement.
Since transforming growth factor-b (TGFb) has been implicated in driving fibrosis in systemic sclerosis, a
mechanism-derived gene expression signature was used to assay TGFb-responsive gene expression in the skin
of patients with systemic sclerosis (SSc). Primary dermal fibroblasts from patients with diffuse SSc (dSSc) and
healthy controls were treated with TGFb, and the genome-wide gene expression was measured on DNA
microarrays over a time course of 24 hours. Eight hundred and ninety-four probes representing 674 uniquely
annotated genes were identified as TGFb responsive. Expression of the TGFb-responsive signature was
examined in skin biopsies from 17 dSSc, seven limited SSc (lSSc), three morphea patients, and six healthy
controls. The TGFb-responsive signature was expressed in 10 out of 17 dSSc skin biopsies, but was not found in
lSSc, morphea, or healthy control biopsies. Expression of dSSC the TGFb-responsive signature stratifies patients
into two major groups, one of which corresponds to the ‘‘diffuse-proliferation’’ intrinsic subset that showed
higher modified Rodnan skin score and a higher likelihood of scleroderma lung disease. The TGFb-responsive
signature is found in only a subset of dSSc patients who could be targeted by specific therapies.
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INTRODUCTION
Systemic sclerosis (SSc) is a systemic autoimmune disease
characterized by skin fibrosis, internal organ dysfunction,
vascular abnormalities, and immune activation. Clinical
presentation is heterogeneous and patients with clinically
indistinguishable early-stage disease progress to different
clinical endpoints. There is a need for objective and
quantitative measures of disease severity that can identify
relative likelihoods of disease progression.
The most widely recognized classification of SSc groups
patients into systemic sclerosis with diffuse scleroderma
(dSSc) and systemic sclerosis with limited scleroderma (lSSc),
largely by the degree of skin involvement (LeRoy et al., 1988).
Efforts have been made to further distinguish the hetero-
geneity in SSc patients (Barnett et al., 1988a, b; Ferri et al.,
2002; Scussel-Lonzetti et al., 2002; Maricq and Valter, 2004),
but no further disease classification has been widely
accepted.
Genome-wide measurement of gene expression with DNA
microarrays can easily distinguish skin biopsies from patients
with dSSc from healthy controls (Whitfield et al., 2003;
Gardner et al., 2006), and identification of gene expression-
based subsets has been reported (Milano et al., 2008).
Multiple distinct gene expression signatures were identified
among patients with scleroderma (Milano et al., 2008), with
some of these groups delineating existing divisions such as
those between dSSc and lSSc, and others reflecting more
subtle changes in the cellular infiltrates or in the expression of
different cellular processes. The signaling pathways under-
lying these subsets have not been mapped. Here we extend
these findings by showing genes responsive to transforming
growth factor-b (TGFb) in vitro are associated with the
‘‘diffuse-proliferation’’ subset of dSSc patients.
Skin fibrosis, generally considered to be driven by TGFb-
activated fibroblasts, is a hallmark of dSSc (Leroy et al., 1989;
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Smith and LeRoy, 1990; Cotton et al., 1998; Leask and
Abraham, 2004; Varga, 2004; Leask, 2006; Verrecchia et al.,
2006; Ihn, 2008). Elevated levels of TGFb have been
observed in SSc skin biopsies (Gabrielli et al., 1993; Sfikakis
et al., 1993) and TGFb-activated fibroblasts produce collagen
I, III, and V in addition to other matrix proteins such as glyco-
aminoglycans (Wynn, 2008). Numerous studies have identi-
fied TGFb-regulated genes that show increased expression in
SSc fibroblasts, including fibronectin (Xu et al., 1991), colla-
gens a1(I) and a1(III) (Kuroda and Shinkai, 1997), collagen-a2(1)
(Jinnin et al., 2006), endoglin (Leask et al., 2002), connective
tissue growth factor (Leask, 2004), and cartilage oligomeric
matrix protein (Farina et al., 2006). SSc fibroblasts also show
an increase in TGFbRI and TGFbRII mRNA levels and surface
protein expression when compared with healthy dermal
fibroblasts (Kubo et al., 2002), suggesting activation of the
TGFb pathway in these cells. Activation of the platelet-deri-
ved growth factor (PDGF) pathway by stimulatory autoanti-
bodies to the PDGF receptor has also been shown and may
target many of the same genes (Baroni et al., 2006). A clinical
trial using anti-TGFb therapy in dSSc patients has been repor-
ted, but the results were inconclusive (Denton et al., 2007).
We report the use of a mechanism-derived gene expres-
sion signature to determine whether a TGFb-response is
found in the gene expression subsets of SSc. We defined a
TGFb-responsive signature over time courses of 24 hours in
four independent cultures of dermal fibroblasts (two healthy,
two dSSc) and identified 894 probes representing 674 TGFb-
responsive genes. The signature was analyzed in vivo in a
microarray data set analyzing skin biopsies from patients with
scleroderma and healthy controls (Milano et al., 2008). The
TGFb-responsive signature is found in the ‘‘diffuse-prolifera-
tion’’ subset of dSSc skin biopsies. This indicates that TGFb
deregulation, or a related pathway, contributes to pathogen-
esis in this subset.
RESULTS
We identified the genes responsive to TGFb on a genome-
wide scale with DNA microarrays in adult dermal fibroblasts
from patients with dSSc and healthy controls. Four indepen-
dent primary fibroblast cultures were analyzed, two from
dSSc lesional forearm skin biopsie, one from a healthy
control forearm skin biopsy, and one commercially available
adult dermal fibroblast culture (Table 1). To compare our
results to prior studies of TGFb responses in fibroblasts, we
used conditions similar to those previously reported
(Chambers et al., 2003; Renzoni et al., 2004). Fibroblasts
were cultured for 7–9 passages post explant in 10% serum
and then brought to quiescence in 0.1% serum for 24 hours
before TGFb treatment. Fewer than 1% of the cells were in
S-phase after 24 hours in 0.1% serum, determined by BrdU
incorporation (data not shown).
To determine optimal experimental conditions, a dosage
curve was generated with 50–300 pM TGFb and the cellular
response measured by quantitative real-time PCR (qRT-PCR).
We found 50 pM TGFb resulted in an 11-fold induction
of plasminogen activator inhibitor 1 (PAI1) mRNA, whereas
treatment with 100 pM TGFb resulted in 16-fold induction
(Figure 1). Concentrations of 200–300 pM resulted in de-
creased relative PAI1 levels, indicating that a concentration
higher than 100 pM was saturating. We chose to use 50 pM for
all further experiments.
Quiescent cells were exposed to 50 pM TGFb and total
RNA was collected at 0, 2, 4, 8 12, and 24 hours after
Table 1. Primary fibroblast cell cultures
Cell line Sex Age Disease duration Biopsy site
Control 1 Male 47 — ND1
Control 2 Female 58 — Forearm
Scleroderma 1 Female 62 1 year Forearm
Scleroderma 2 Male 41 1 year Forearm
Clinical characteristics of individuals from whose biopsies dermal
fibroblasts were obtained.
1Adult dermal fibroblast primary cell line obtained from a commercial
source. Site not determined (ND).
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Figure 1. Dosage and time dependence of plasminogen activator inhibitor 1
(PAI1) mRNA expression after TGFb treatment. To optimize the
concentration of TGFb and the length of time course to analyze, cells were
treated with varying doses of TGFb, and time points were collected from 2 to
24hours. (a) Normal dermal fibroblasts (NDFs) in 0.1% serum were treated
with 50, 100, 200, or 300 pM TGFb for 2 hours. Levels of PAI1 mRNA were
measured in triplicate by Taqman qRT-PCR, normalized to 18S rRNA; fold
change is relative to the average of three independent, untreated samples. (b)
NDFs were treated with 50 pM TGFb and PAI1 mRNA levels were measured in
triplicate at 0, 2, 4, 8, 12, and 24 hours post-treatment. Fold change is relative
to the average of the zero time points.
www.jidonline.org 695
JL Sargent et al.
TGFb-Responsive Signature in Scleroderma
treatment. A mock time course without TGFb, but in
otherwise identical conditions, was performed in a single
culture of normal dermal fibroblasts. The mock time course
identifies genes that may respond to treatment effects that are
independent of TGFb. Total RNA from each sample was
amplified, labeled, and hybridized to whole-genome DNA
microarrays in a common reference design. Eight microarrays
were hybridized for each time course resulting in a total of 40
microarray hybridizations.
Genome-wide response to TGFb in adult dermal fibroblasts
To characterize the genome-wide response to TGFb
across the four independent fibroblasts cultures, probes
were selected that changed at least 1.74-fold in at least
eight of the 32 arrays. Eight hundred and ninety-four
TGFb-responsive probes were selected representing 674
uniquely annotated genes (Figure 2a and Supplementary
Data File 1). The gene expression data for eight probes
corresponding to seven known TGFb targets in dermal
fibroblasts is shown (Figure 2b). Examination of these probes
in the mock, no TGFb, control shows that the observed
changes in gene expression are specific to a TGFb response
(Figure 2a).
To identify differential TGFb responses between normal
and scleroderma fibroblasts, the data from TGFb-treated
normal fibroblast was compared to that of TGFb-treated
SSc fibroblasts with significance analysis of microarrays
(SAM) using slope and area functions, in a two-class unpaired
time-course analysis. Only a single gene, Early Growth
Response-1 (EGR1), was significantly differentially induced at
an false discovery rate (FDR) o5%. Since one would expect
this number or more to be called as falsely significantly by
chance alone, this is likely a false positive. Another recent
study also failed to find significant differences in the TGFb
responses in cultured lung fibroblasts from SSc patients and
normal controls (Chambers et al., 2003).
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Figure 2. Genome-wide response to TGFb in adult dermal fibroblasts. (a) Shown are the 894 probes, representing 674 annotated genes, with a 1.74-fold
or greater change in expression over 24 hours following treatment with 50 pM TGFb. Four independent primary cell cultures were treated with TGFb, two
from healthy control subjects (blue), and two from SSc patients (orange). A mock time course was performed using identical conditions with the omission
of TGFb. Time of treatment, from 0 to 24 hours, is indicated. Each row represents a probe, and each column represents a time point. (b) Expression data for
the genes previously reported as being TGFb responsive (Supplementary Table S2) and found among the 894 probes. (c) Module map of GO terms in the
genome-wide response to TGFb. Each column represents a microarray, and each row represents an enriched GO term. Only modules that were significantly
enriched (Po0.05) in at least 16 microarrays analyzed are shown. Select modules are indicated.
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TGFb module map
To summarize the biological programs represented by
genes in the TGFb-responsive signature, we created a
module map that identifies groups of Gene Ontology
(GO) terms (biological process, cellular component, or
molecular function) coordinately regulated by TGFb in
cultured adult dermal fibroblasts. Each row shows a unique
module that is a set of coordinately regulated genes involved
in similar processes.
Modules with significantly enriched genes (Po0.05,
hypergeometric distribution) in at least 16 of the 20 arrays
were selected. A subset of modules is shown (Figure 2c); the
full figure with all modules is available as Supplementary
Figure S1. Those induced after TGFb treatment included pro-
teinaceous extracellular matrix, extracellular matrix, and extra-
cellular space, associated with collagen production, extracel-
lular matrix deposition, and remodeling (Figure 2c). TGFb is a
mediator of fibrosis in different organs including skin, kidneys,
lungs, and liver, and is necessary for tissue remodeling and
wound healing (Varga and Whitfield, 2009; Wynn, 2008).
Modules associated with development programs included
angiogenesis, skeletal development, muscular development,
vasculature development, multicellular organismal develop-
ment, organ morphogenesis, and anatomical structure morpho-
genesis. The role of TGFb and its family members in
embryogenesis, tissue specification, and organ develop-
ment through to tissue maintenance and repair have been
extensively characterized (Wall and Hogan, 1994; Padgett
et al., 1997; Mummery, 2001).
Among the enriched, downregulated GO terms were
mitotic cell cycle, cell division, and chromosomal segrega-
tion, indicating that TGFb downregulates the proliferation
signature (Whitfield et al., 2006) under low-serum conditions.
TGFb-responsive gene expression underlies the
‘‘diffuse-proliferation’’ intrinsic subset
To determine whether the TGFb-responsive signature was
expressed in the intrinsic subsets of scleroderma, we
analyzed the expression of the 894 TGFb-responsive signa-
ture probes (674 genes) in the data set of Milano et al. (2008),
which included dSSc, lSSc, morphea, and healthy controls.
Expression data for each of the 894 probes was extracted
from the set of 75 microarrays and organized by hierarchical
clustering (Figure 3). Organization of the samples was
Intrinsic weight < 0.30
995 genes
Diffuse 1
TGFβ-activated TGFβ-not activated
Enriched for dSSC patients
(P<0.001, 2) 
Diffuse 2 Inflammatory
*
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Figure 3. TGFb-responsive genes are deregulated in the ‘‘diffuse-proliferation’’ subset of scleroderma. (a) Intrinsic subsets of scleroderma as described by
Milano et al. (2008). (b) Organization of 75 arrays from Milano et al. by hierarchical clustering of 894 TGFb-responsive signature genes. Shading is indicative of
positioning of subsets identified by intrinsic genes relative to that identified by the TGFb-responsive signature. *Po0.001.
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compared to the sample groupings reported using an intrinsic
gene set (Milano et al., 2008). The group expressing the
TGFb-responsive signature is similar to the diffuse-prolifera-
tion subset (Supplementary Table S1), suggesting that
deregulated TGFb signaling, or a related pathway, may
underlie this subset. Several related pathways and modulators
have been implicated in SSc, including endoglin, which has
increased expression on endothelial cells (Dharmapatni
et al., 2001), and fibroblasts (Leask et al., 2002), endothe-
lin-1, which is a downstream mediator of TGFb responses,
(Shi-Wen et al., 2007), and the related PDGF pathway,
implicated by the presence of stimulatory autoantibodies to
the PDGF receptor (Baroni et al., 2006). Activation of the
PDGF pathway in SSc has proven controversial (Classen
et al., 2009). Consistent with deregulation of the TGFb and
PDGF pathways, several studies have demonstrated that
imatinib mesylate prevents fibrosis in murine models of
fibrosis (Daniels et al., 2004; Distler et al., 2007; Akhmet-
shina et al., 2008). Additionally, a case report showed a gene
expression response associated with disease improvement
in two patients after treatment with imatinib mesylate
(Chung et al., 2009).
Samples with high expression of the TGFb-responsive
signature include only dSSc skin biopsies, and this enrich-
ment is statistically significant (Po1 104, w2-test). One
patient classified as diffuse-proliferation and one patient
classified as inflammatory did not show consistent expression
of the TGFb-responsive signature (Supplementary Table S1).
Therefore, there is not a precise overlap of the TGFb-
responsive group and the proliferative group identified by
Milano et al. The group without the TGFb-responsive
signature contains a subset of the dSSc biopsies, all lSSc
biopsies, morphea samples, and healthy controls. Therefore,
the TGFb-responsive signature, a set of genes independent
from the 995 intrinsic genes, is expressed in a subset of dSSc
patients, but is not expressed in lSSc, morphea, or healthy
controls.
TGFb-responsive gene expression in dSSc patients
To determine whether the TGFb-responsive gene signature
was consistently found in both lesional and non-lesional skin,
or associated with specific clinical phenotypes, we analyzed
the signature in the diffuse patients alone. The expression
values for each of the 894 genes in the TGFb-responsive
signature were extracted from the skin biopsy data set and
the 53 microarrays representing only patients with dSSc and
normal controls. Samples were ordered by hierarchical
clustering; the resulting sample dendrogram shows clear
bifurcation of the skin biopsies (Figure 4a). The left branch,
highlighted in red, is comprised solely of samples from dSSc
patients, while the right branch includes the remaining dSSc
samples and all healthy controls. Samples from two patients,
dSSc2 and dSSc8, split between the two groups and,
therefore, could not be assigned to either group. Of the
patients who were consistently classified, each showed
deregulation of the TGFb-responsive gene signature in both
lesion forearm and non-lesion back biopsies. Therefore, the
systemic nature of the disease extends to specific pathways.
The significance of the classification was determined with
Statistical Significance of Clustering (SigClust) (Liu et al.,
2008), which tests the robustness of the sample bifurcation
and found that the clustering is highly significant (Po0.001).
We find the TGFb-activated group to be a single statistically
significant cluster. The TGFb-not-activated group forms two
statistically significant clusters. We did not further investigate
this additional sub-grouping given the relatively small size of
the groups.
Alignment of the skin biopsy gene expression data with
that from the in vitro TGFb time courses reveals that
expression of the signature is heterogeneous (Figure 4b).
We identified the subset of the 894 probes driving the sample
bifurcation. A two-class unpaired SAM analysis identified 474
probes to be significantly differentially expressed between the
two groups (FDRo1.15%; Figure 5). The centroid for the 474
differentially expressed probes is shown (Figure 5 and
Supplementary Data File 2). The activation of the TGFb-
responsive signature in each patient sample was determined
by calculating the Pearson correlation coefficients between
the centroid and the gene expression for each skin biopsy
(Figure 5). For simplicity, we have termed the group on the
left (red dendrogram) TGFb-activated because of high
positive correlation coefficients associated with these sam-
ples, and the group on the right (black dendogram) TGFb-not
activated owing to the predominantly negative correlation
coefficients.
The genes in Figure 5 can be classified into two groups
based on their expression patterns in the fibroblast time
courses and skin biopsies. Those concordantly and those
discordantly expressed between fibroblasts and skin, and
further characterized as up- or downregulated in fibroblasts
upon TGFb treatment. Genes found concordantly upregu-
lated in TGFb-stimulated fibroblasts and skin included
canonical targets ID3, PDGFA, SPHK1 (Supplementary Table
S2), genes involved in organ and tissue development (HOXB2
and HOXC8), and genes associated with apoptosis (ENC1
and CARD4). Genes concordantly downregulated included
those involved in cell signaling (PDGFRA and IL6R) and
phospholipids binding (PLD1 and PIK3C2B).
Genes induced in the TGFb-treated fibroblasts, but with
low expression in the TGFb-activated skin biopsies, were
enriched for developmental processes and signaling (RUNX2,
BMPR2, and BMP6). Genes showing decreased expression in
TGFb-treated fibroblasts, but increased expression in the skin
biopsies, were those associated with cell cycle (the prolifera-
tion signature; Whitfield et al., 2006; CDCA2, CDCA8,
CCNB2, and CENPF). High expression of these genes was
observed previously in the diffuse-proliferation subset and we
found increased KI67 staining in the epidermis of the skin
biopsies (Milano et al., 2008).
Validation of TGFb signature genes in patient samples
We validated the expression of three genes from the TGFb-
responsive signature, which were also the most highly
differentially expressed between the groups with and without
the TGFb-responsive gene signature (Figure 6). We analyzed
the expression of E2F7, which is also a cell-cycle-regulated
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gene (Whitfield et al., 2002), growth differentiation factor-6,
which is a member of the TGFb superfamily, and actin-a2.
Each gene was measured in representative patient samples by
qRT-PCR (Figure 6a–c) and compared to the expression levels
from the DNA microarray (Figure 6d–f), in all cases the gene
expression follows the same trends between the TGFb-
activated versus TGFb-not-activated groups.
The TGFb-responsive signature is associated with more severe
skin and lung disease
We examined the severity and incidence of available clinical
parameters, calculated both by patient and by biopsy, to
determine whether the dSSc patients in the TGFb-activated
group showed phenotypic differences from those in the
TGFb-not-activated group. Since patients dSSc2 and dSSc8
could not be accurately assigned, they were excluded from
the analysis, leaving 10 patients in the TGFb-activated group
and five in the TGFb-not-activated group. Each group was
analyzed for differences in clinical covariates (Table 2).
Student’s t-tests were used to analyze differences in patient
age, disease duration as defined by onset of first non-Raynaud
symptoms, mean modified Rodnan skin score (MRSS) (0–51),
Raynaud phenomenon (0–10), and digital ulcers (0–3). All
other parameters for which we had clinical data, including
incidence of interstitial lung disease (ILD), impaired renal
function, and gastrointestinal involvement were scored as
either present or absent and a w2-test used to assess
differences between the groups (Table 2). When individual
biopsies were considered, the TGFb-activated group showed
significantly higher skin scores (mean¼26.9±2.04) than the
TGFb-not-activated group (mean¼ 17.8±1.95; P¼0.0061).
When performed on a per patient basis, the difference in the
means is weakly significant (P¼0.11). Examination of the dot
plots for MRSS shows consistent difference in the means, with
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Figure 4. The TGFb-responsive signature distinguishes a subset of dSSc patients. (a) Patient sample dendrogram resulting from hierarchical clustering
of 53 arrays probing gene expression in skin biopsies of patients with dSSc (orange bars) and healthy control (blue bars). The samples were clustered using the
894 TGFb-responsive probes that comprise the signature. Two major groups of samples are evident: TGFb-activated (red) and TGFb-not-activated (black).
Technical replicates are designated by a letter (a, b or c) following patient and biopsy site identification. Statistically significant clusters as determined by
SigClust are marked by *(Po0.001). (b) Individual TGFb time courses are aligned with the gene expression data from dSSc and healthy control biopsies,
and illustrate the heterogeneity of the in vitro–derived TGFb-responsive signature in skin biopsies.
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no significant outliers (Figure 7). We found that ILD was
significantly more prevalent among the TGFb-activated
samples (7 of 16) as compared with TGFb-not-activated
group (0 of 10; P¼ 0.014; Table 2), with an odds ratio of
E16.58. When patients rather than biopsies are considered,
then five out of 10 patients in the TGFb-activated group had
ILD, whereas none of the five patients in the TGFb-not-
activated group had ILD (P¼ 0.053). Since this type of
exploratory analysis has not been performed previously, we
are more concerned about type-II errors (false negatives) than
type-I errors (false positives). As such, we consider the
P-value of 0.053 to be strongly suggestive, although it does
not meet a strict 0.05 significance level, and should be
considered a hypothesis that should be tested in a larger
cohort of patients. The analysis by biopsy is important
because it shows the TGFb signature is reproducible from
different skin samples (lesion forearm and non-lesion back)
from the same patient. We found only a weak association
with disease duration (biopsies, P¼0.086; patients,
P¼0.14). Examination of the dot plots of disease duration
shows that the TGFb-activated group is skewed by two
outliers from patients with disease durations of 20 years
(Figure 7). We found no significant associations with any of
the other clinical variables, including potential immune
modulating therapies or with anti-topoisomerase-I status
(Table 2).
DISCUSSION
Experimental determination of a mechanism-derived TGFb
signature in fibroblasts has allowed us to analyze the genes
responsive to this pathway in skin biopsies from patients with
scleroderma and healthy controls. This has shown that the
TGFb-responsive gene signature is expressed heteroge-
neously across the spectrum of scleroderma, but shows high
expression in a subset of dSSc patients with higher MRSS and
increased incidence of lung involvement. The TGFb-respon-
sive signature is not found in patients with lSSc, morphea, or
in healthy controls. Given the established role for TGFb in
mediating fibrosis, it is not surprising that such a signature
shows increased expression in dSSc skin, but the hetero-
geneity of expression among the SSc patients was not
expected. This provides further evidence for subsets of
patients that can be distinguished by gene expression and
demonstrates that this heterogeneity extends to the pathway
level. Most importantly, it suggests that TGFb activation, or
activation of a related pathway such as PDGF, may underlie
the ‘‘diffuse-proliferation’’ subset of scleroderma.
The finding that a gene signature expressed in skin is
associated with the occurrence of lung disease is surprising
and to our knowledge is previously unreported. ILD is the
leading cause of death among patients with dSSc and
approximately 70% of patients show evidence of significant
lung pathology at autopsy (Ostojic et al., 2007; Steen and
Medsger, 2007). Recent work has developed tools and
methods for diagnosis, staging, and characterization of ILD
in dSSc patients (Goh et al., 2008); however, biomarkers that
reliably predict who will develop lung complications before
they become symptomatic would be beneficial. Surprisingly,
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Figure 6. Validation of TGFb-responsive genes in dSSc skin. Relative mRNA levels of three genes, E2F7 (a, d), growth differentiation factor-6 (b, e), and
actin-a2 (c, f) were determined using Fast Taqman qRT-PCR on select patient samples from the TGFb-activated and TGFb-not-activated patient groups.
Trends of mRNA levels determined by qRT-PCR were reflective of those measured on DNA microarrays (d–f). All data were normalized to the mean
relative expression ratio.
Table 2. Clinical parameters associated with the TGFb-responsive signature
Clinical parameter
Activated
(16 biopsies)
Not activated
(10 biopsies) P-value
Activated
(10 patients)
Not activated
(5 patients) P-value
Patient age (years) 46.3±2.55 50.6±2.33 0.26 48.0±3.43 50.6±3.50 0.64
Disease duration (years) 7.63±1.41 4.00±1.19 0.086 9.00±2.04 4.40±4.07 0.14
MRSS 26.9±2.04 17.8±1.95 0.00611 25.2±2.63 17.8±2.92 0.11
Lung disease 7/16 0/10 0.0142 5/10 0/5 0.053
GI involvement 14/16 6/10 0.11 9/10 3/5 0.17
Renal disease 2/16 0/10 0.24 2/10 0/5 0.28
Raynaud severity 5.93±0.57 7.00±0.99 0.33 5.33±0.78 7.00±1.48 0.29
Digital ulcers 0.50±0.18 0.80±0.38 0.44 0.50±0.22 0.80±0.58 0.57
Immunosuppressive therapy 9/16 2/10 0.069 5/10 1/5 0.26
Anti-topoisomerase-I3 6/12 2/6 0.502 3/6 1/3 0.64
MRSS, modified Rodnan skin score; TGFb, transforming growth factor-b.
Statistical associations of clinical parameters with the TGFb-activated and TGFb-not-activated groups of patients. Associations with MRSS, disease duration,
patient age, Raynaud severity, and digital ulcers were calculated using Student’s t-tests (mean±SEM). Associations with ILD, GI involvement, renal disease,
and presence of anti-topoisomerase antibodies were determined by w2-test (1Po0.01, 2Po0.02). Calculations were performed by biopsy (columns 2–4) and
by patient (columns 6–7).
3Data on the anti-topoisomerase-I status were only available for six patients (12 biopsies) in the activated group and three patients (six biopsies) patients in
the not activated group.
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only a weak association was found between the TGFb-
responsive gene signature and disease duration, raising the
possibility that the signature is stable over the disease course
in this subset of patients.
Concordance between the TGFb-responsive gene signa-
ture defined in vitro and that found in vivo is variable. Gene
expression observed in skin is likely influenced by multiple
soluble factors and signals from the extracellular matrix.
Thus, the heterogeneity of the signature in skin likely results
from differences between single-cell-type cultures stimulated
with a single cytokine versus the complexity of whole skin
that contains multiple cell types in distinct tissue-specific
niches. In addition, many TGFb-responsive genes are also
responsive to other profibrotic cytokines and signaling mole-
cules such as IL13, IL4, spingosine-1 phosphate (JL Sargent
and ML Whitfield, unpublished data), endoglin (Dharmapatni
et al., 2001; Leask et al., 2002; Fujimoto et al., 2006; Wipff
et al., 2007), endothelin-1 (Shi-Wen et al., 2007), but also
PDGF and fibroblast growth factor (Gu and Iyer, 2006). Both
endothelin-1 (Shi-Wen et al., 2007) and PDGF have been
implicated in SSc pathogenesis (Baroni et al., 2006). There-
fore, multiple profibrotic signaling pathways converge on this
set of genes, which almost certainly contributes to the
signature variability in the TGFb-activated group.
The 674 genes of the TGFb-responsive signature defined
here were compared to two previously published studies of
TGFb-responsive genes in human fibroblasts. Chambers et al.
(2003) analyzed human fetal lung fibroblast and identified
122 TGFb-responsive genes, of which 58 (48%) were
identified as TGFb-responsive in our study. Renzoni et al.
(2004) analyzed adult lung fibroblasts and identified 128
TGFb-responsive genes, of which 33 (26%) were identified in
our study. Only 11 genes were identified by both Renzoni
and Chambers, all of which are found to be TGFb-responsive
here. The limited overlap found among the different
signatures is not surprising given the differences in fibroblasts
from different anatomical sites (Chang et al., 2002; Rinn
et al., 2006), the use of different microarray platforms, and
different analysis techniques.
We have previously described subsets of scleroderma
patients distinguished by unique gene expression signatures
found in both lesional (forearm) and non-lesional (lower
back) skin (Milano et al., 2008). The association of the TGFb-
responsive signature with both the lesional and non-lesional
skin is an important validation of the systemic gene
expression in skin.
MATERIALS AND METHODS
The gene expression data from lesional forearm and non-lesional
back skin of scleroderma, and of healthy skin biopsies, has been
previously described (Milano et al., 2008). All work with human
subjects or materials was performed with adherence to the
Declaration of Helsinki Principles. All subjects signed consent forms
approved by the Committee on Human Research at the University of
California, San Francisco. Patients met the ACR criteria for systemic
sclerosis and were further defined as the diffuse subset. The
Committee on the Protection of Human Subjects approved all
protocols at Dartmouth Medical School.
All clinical measurements were taken at time of biopsy and have
been described in detail previously (Milano et al., 2008). Briefly, as
part of the patients’ routine scleroderma standard of care, patients
were assessed for MRSS on a 51-point scale, disease duration since
first onset of non-Raynaud’s symptoms, a self-reported Raynaud
severity score on a 10-point scale, and presence or absence of digital
ulcers on a three-point scale. Also recorded were presence (þ ) or
absence () of gastrointestinal involvement, scleroderma lung
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Figure 7. Distributions of MRSS and disease duration of dSSc patients. Distributions of MRSS at the time of biopsy were plotted by biopsy (a) and by
patient (b) for the TGFb-activated and TGFb-not-activated groups. Distributions of disease duration were also plotted by biopsy (c) and by patient (d) for the
two groups. P-values for all comparisons are given in Table 2.
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disease, which included patients defined as having pulmonary
fibrosis or patients with ILD as determined by ground glass
appearance, fibrosis or honeycombing on high-resolution computer-
ized tomography, renal disease, and anti-topoisomerase antibodies.
Data from patients on immunosuppressive therapy (mycophenolate
mofetil, methotrexate, azathioprine, or prednisone 410mg daily)
were also recorded.
Cells and cell culture
Primary adult human dermal fibroblasts were purchased from
Cambrex Bioscience Inc. (East Rutherford, NJ) Additional adult der-
mal fibroblasts were isolated from explanted healthy or dSSc lesional
forearm skin biopsies (Table 1) cultured for at least three passages in
DMEM, 10% (v/v) fetal bovine serum, penicillin-streptomycin
(100 IU/ml) at 37 1C in a humidified atmosphere with 5% CO2. Cells
were passaged every 7 days for 7–10 passages prior to treatment.
BrdU staining
Cell proliferation was assessed with BrdU Labeling and Detection kit I
(Roche Applied Sciences, Penzberg, Germany). BrdU incorporation
was detected according to the manufacturer’s instructions, counter-
stained with 40-6-diamidino-2-phenylindole, and visualized with an
Olympus BX51 microscope.
RNA preparation
For analysis of the TGFb response, 4 105 cells were grown in
100-mm dishes and cultured in DMEM with 10% fetal bovine
serum for 48 hours. Cells were brought to quiescence by culturing in
low-serum media, DMEM with 0.1% fetal bovine serum, for
24 hours. TGFb derived from human platelets (R&D Systems,
Minneapolis, MN) was diluted into low-serum media and used to
treat cells for 0, 2, 4, 8, 12, and 24 hours. Following treatment with
TGFb, cells were lysed in RLT buffer with b-mercaptoethanol
and total RNA was isolated with RNeasy minikits (Qiagen,
Valencia, CA).
Microarray procedures
Microarray protocols have been described in detail (Milano et al.,
2008). Total RNA (300–500 ng) was amplified and labeled according
to Agilent Low RNA Input Fluorescent Linear Amplification
protocols. Each experimental RNA sample was labeled with
Cy3-CTP and competitively hybridized against Universal
Human Reference RNA (Stratagene, La Jolla, CA) labeled with
Cy5-CTP on Agilent 44,000-element Human microarrays.
Microarrays were scanned with a GenePix 4000B scanner and
acquired images quantified with the GenePix Pro 5.1 software (Axon
Instruments, Foster City, CA). Technical artifacts and poor-quality
spots were flagged and excluded from further analysis. Data were
loaded to the UNC Microarray Database.
Data analysis
Data were analyzed as log2 of the lowess-normalized Cy5/Cy3 ratio.
A total of 18,696 probes with fluorescent signal at least 1.5 greater
than local background and of good quality in at least 80% of arrays
were selected for analysis. Each data table was multiplied by
negative one to convert the log2 ratios to Cy3/Cy5 ratios and then
T0-transformed using the average of triplicate 0-hour samples.
TGFb-responsive probes were selected by fold-change cutoff and
genes were hierarchically clustered using the Cluster 3.0 software
(Eisen et al., 1998). Centroid values for each gene were calculated by
averaging the T0-transformed data for the 12- and 24-hour time
points across all TGFb treatment time courses. The optimal fold-
change threshold was determined by comparing genes induced or
repressed by the addition of TGFb over a range of threshold values to
a list of 15 known TGFb targets in human fibroblasts complied from
the literature (Supplementary Table S2). At a 1.74 fold-change
threshold we identified seven of the 15 (47%) known TGFb targets in
the microarray time-course data. Analyzing this same list of genes in
two published TGFb signatures from pulmonary fibroblasts identified
three (20%) (Renzoni et al., 2004) and six (40%) (Chambers et al.,
2003) of the fibroblasts targets. A less stringent fold-change threshold
did not significantly increase the fraction of known targets identified.
Therefore, we elected to use the 1.74 fold-change threshold to define
TGFb-responsive probes.
Module maps were created with Genomica (Segal et al., 2003).
Expression data for probes that mapped to the same gene were
averaged. Probes lacking entrez gene identifiers were excluded,
yielding 10,664 unique genes for analysis. Gene sets of GO
biological processes for the module map analysis were obtained
from http://genomica.weizmann.ac.il.
Microarray data analyzing scleroderma skin are available from
GEO (accession no. GSE9285) (Milano et al., 2008). The patient data
set consisting of biopsies from 17 dSSc patients and six healthy
controls (53 arrays in total) was downloaded from UNC Microarray
Database. A total of 40,818 probes with fluorescent signal at least
1.2-fold greater than local background and of good quality in at least
80% of arrays were selected for analysis.
Statistical analysis of clustering of the patient samples was
performed with SigClust (Liu et al., 2008). Heat maps were generated
and visualized using TreeView version 1.0.13 (Eisen et al., 1998).
Quantitative real-time PCR
Total RNA (100–200ng) was reverse-transcribed into single-stranded
complementary DNA using SuperScript II reverse transcriptase
(Invitrogen, San Diego, CA). Complementary DNA (1.25mg) was
used for each qRT-PCR reaction. Primer probes sets for PAI1
(NM_00602.2), 18S (X03205.1), E2F7 (NM_203394.2), growth differ-
entiation factor-6 (NM_001001557.1), actin-a2 (NM_001141945.1),
and glyceraldehyde-3-phosphate dehydrogenase (NM_002046.3)
were obtained from Applied Biosystems (Foster City, CA) and
analyzed using either the 7300 Real-Time PCR System or the
7,500 Fast Real-Time PCR system. The number of cycles required
to generate a detectable fluorescence above background (Ct) was
measured for each sample. For dose–response and time-course
analyses, fold changes were calculated relative to the average of
triplicate untreated samples by the comparative Ct formula 2
DDCt
(Livak and Schmittgen, 2001), where DCt is the difference between
the target gene (PAI1) and the 18S rRNA control, and DDCt is the
difference between the DCt value of the target gene and the average
of the DCt values of untreated triplicate samples.
Statistical methods
Statistical calculations were performed using Prism for Macintosh
V4.0a (GraphPad Software Inc., La Jolla, CA) or Microsoft Excel with
the add-in Winstat. Where indicated, SAM was used to identify
significantly differentially expressed genes (Tusher et al., 2001).
www.jidonline.org 703
JL Sargent et al.
TGFb-Responsive Signature in Scleroderma
Data access
Microarray data have been deposited at GEO (http://www.ncbi.
nlm.nih.gov/geo/; accession no. GSE12493). The complete data set
and searchable versions of the figures are available at http://
whitfieldlab.dartmouth.edu/TGFB/.
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